ImmunityBio appoints Dr Jim Yong Kim as Vice Chairman
He will lead the new Office of the Executive Chairman, focusing on international partnerships and global access initiatives.
Latest ImmunityBio News & Updates
See the latest news and media coverage for ImmunityBio. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing immunotherapies for cancer and infectious diseases
immunitybio.com- Headquarters
- San Diego, United States
- Founded year
- 2014
- Company type
- Public company
- Number of employees
- 600–1,000
- Industry
- Pharmaceuticals
Last updated
Latest news about ImmunityBio
In short: ImmunityBio posted record $50.7M Q2 revenue, expanded ANKTIVA to 34 countries via UAE approval, and advanced its FDA bladder-cancer sBLA.
Company announcements
ImmunityBio reports record Q2 product revenue of $50.7 million
First-half revenue rose 121% to $94.8 million; cash totals $357.4 million; FDA accepted sBLA for ANKTIVA plus BCG.
ImmunityBio receives UAE marketing authorization for ANKTIVA
The authorization covers BCG-unresponsive NMIBC and metastatic NSCLC, expanding to 34 countries.
ImmunityBio presents new data across lung and bladder cancers
The data includes Phase 3 trial results in advanced NSCLC and a comparative analysis in BCG-unresponsive NMIBC.
Media coverage
FDA issues warning letter to ImmunityBio over misleading promotion of NAI | Urology Times
ImmunityBio has submitted a formal response to the FDA and initiated corrective actions.
ImmunityBio Stock Soars 11% as Anktiva Momentum and FDA Catalyst Hopes Fuel Rally in Soon-Shiong's Biotech
ImmunityBio shares rose more than 11% as investors weighed accelerating Anktiva sales, international expansion, regulatory milestones and the FDA's planned January 2027 decision on broader...
ImmunityBio (IBRX) Meeting With Turkish President Fuels Expansion Hopes, Shares Climb 10%
ImmunityBio Inc. (NASDAQ:IBRX) saw its share price jump by 9.94 percent on Tuesday to finish at $9.29 apiece following a high-profile meeting between its founder...
2026-09-20 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ImmunityBio, Inc. (IBRX) And Encourages Shareholders to Reach Out | NDAQ:IBRX | Press Release
(2026-09-20 | NDAQ:IBRX) Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ImmunityBio, Inc. (IBRX) And Encourages Shareholders to Reach Out...
Never miss news about ImmunityBio
Track ImmunityBio and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
ImmunityBio competitors & trending companies
Browse news for competitors to ImmunityBio and other trending companies.